ADC Therapeutics SA
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ADC Therapeutics SA generated cash of -$118,686,000, which is more than the previous year. Cash used in financing activities reached the amount of $73,875,000 last year. Net change in cash is therefore -$47,843,000.
Cash Flow
| 2017 | -74.94M | -3.24M | 197.23M |
|---|---|---|---|
| 2018 | -121.36M | -2.50M | -24K |
| 2019 | -121.58M | -2.24M | 100.51M |
| 2020 | -168.72M | -2.82M | 494.96M |
| 2021 | -233.37M | -6.67M | 267.39M |
| 2022 | -136.79M | -2.50M | -593K |
| 2023 | -118.68M | -3.21M | 73.87M |
ADCT Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 326.44M | 466.54M | 439.19M | 115.55M | 138.80M | 262.75M | 143.66M |
Operating activities | |||||||
Net income | -240.05M | -155.8M | -230.02M | -246.29M | -116.48M | -123.09M | -89.86M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 3.26M | 2.32M | 2.63M | 2.18M | 1.64M | 740K | 341K |
Stock-based compensation expense | 13.49M | 49.32M | 60.48M | 37.58M | 1.11M | 0 | 980K |
| Deferred income tax benefit | 13.49M | 49.32M | 60.48M | 37.58M | 1.11M | 0 | 980K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 47.78M | -42.75M | -30.21M | 0 | 192K | 895K | 4.82M |
Inventories | 1.60M | -8.96M | -3.02M | 0 | -2.31M | 1.58M | 5.02M |
Accounts payable | 3.17M | 310K | 6.79M | 1.92M | -3.42M | -858K | 5.46M |
Cash generated by operating activities | -118.68M | -136.79M | -233.37M | -168.72M | -121.58M | -121.36M | -74.94M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.21M | -2.29M | -6.37M | -2.80M | -2.14M | -2.47M | -3.15M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -3.21M | -2.50M | -6.67M | -2.82M | -2.24M | -2.50M | -3.24M |
Financing activities | |||||||
Common Stock Issued | 773K | 6.13M | 778K | 433.15M | 41K | 0 | 197.23M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -221K | 0 | 0 | -141K | -24K | 0 |
Repayments of term debt | 0 | -2.70M | -977K | -1.14M | -1.00M | 0 | 0 |
Cash used in financing activities | 73.87M | -593K | 267.39M | 494.96M | 100.51M | -24K | 197.23M |
Net Change In Cash | -47.84M | -140.10M | 27.34M | 323.64M | -23.25M | -123.94M | 119.08M |
Cash at end of period | 278.59M | 326.44M | 466.54M | 439.19M | 115.55M | 138.80M | 262.75M |
| Data source | Data source | Data source | Data source |